LOOK AT THIS IF YOU'RE INTERESTED IN:
Learning the revised recommendations from WHO on the use of HPV vaccines.
HOW YOU CAN USE THIS MATERIAL:
Immunisation programme managers and decision-makers can use these updated guidelines to optimize their national HPV schedule and improve access and coverage of the vaccine.
OVERVIEW:
WHO has updated its recommendations for the human papillomavirus (HPV) vaccine in a position paper published in December 2022. The position paper states that a single-dose schedule, referred to as an alternative, off-label single–dose schedule, can provide a comparable efficacy and durability of protection to a two-dose regimen. The optimization of the HPV schedule is expected to improve access to the vaccine, offering countries the opportunity to expand the number of girls who can be vaccinated and alleviating the burden of the often complicated and costly follow-up required to complete the vaccination series. It’s vital that countries strengthen their HPV vaccination programmes, expedite implementation, and reverse the declines in coverage experienced during the Covid-19 pandemic.